Eisai
Manufacturing · Japan · 10K+ Employees
View Company Info for Free
Overview
Headquarters
4-6-10 Koishikawa Bunkyo-ku, Tokyo, Kant...Phone Number
+81 338173700Website
www.eisai.co.jpRevenue
$5.2 BillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Eisai
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment oRead more
Eisai Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eisai your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Eisai
Product Launch: Get notified when Eisai launches new products
Click to see if Eisai had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Eisai has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Eisai recently announced quarterly report
Check out if Eisai is spiking on competitors!
Eisai, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Eisai has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Eisai is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eisai is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eisai.
Eisai Tech Stack
A closer look at the technologies used by Eisai
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Eisai News & Media
Complex Messaging, Outstanding Designs: Our Top 10 Exhibits at ASCO 2026
The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting brought together more than 40,000 professionals at McCormick Place in Chicago May 29 through June 2 to explore the latest advances in cancer research, clinical practice, and innovation. Exhibiting at a medical congress comes with a unique rulebook. Commercial and medical affairs functions must remain […] The post Complex Messaging, Outstanding Designs: Our Top 10 Exhibits at ASCO 2026 appeared first on Chief Marketer.Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer's Disease and Related Dementias
Expansion of Magnolia Meals at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners NUTLEY, N.J., June 1, 2026 /PRNewswire/ -- Eisai Inc. today announced the expansion of its Magnolia Meals at Home® program to support the...EISAI TO BEGIN ENROLLING PHASE 2 STUDY IN PATIENTS WITH NARCOLEPSY
NUTLEY, N.J., March 26, 2026 /PRNewswire/ -- Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study...Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
TOKYO, Mar 12, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it is launching an initiative to raise public awareness of the importance of sleep in collaboration with the smartphone application “Pokémon Sleep”. It is estimated that 12.4 million adults in Japan—equivalent to 11.8% of the adult population—experience insomnia and the resulting daytime functional impairments.1 According to the 2023 National Health and Nutrition Survey by
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eisai
Sign Up For FreeTo access detailed company insights
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provide... Read More
